This article was originally published in The Rose Sheet
In preliminary first quarter results, Dusseldorf, Germany company announces that the cosmetics and toiletries business achieved organic sales growth of 3 percent to about $939 million, and operating profit advanced 3.4 percent to $117.4 million. A 19 percent decrease in organic sales of the adhesives technology business dragged total organic sales down 7 percent to $4.24 billion, though net sales increased 3 percent. Operating profit declined 32.8 percent to $280.4 million. Though the firm says it is dissatisfied with its results, it has the strength to emerge from the difficult economic environment and believes 2009 will be a "major step towards achieving our long-term targets.
You may also be interested in...
PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.
Increased uptake for generics and biosimilars must become Belgium’s “new normal” in the wake of the coronavirus crisis, local off-patent industry association Medaxes has argued.
Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.